- 24 h
- letzte 200 News
| Zeit | Aktuelle Nachrichten | ||
|---|---|---|---|
| Mi | Ascletis's daily acne tablet set for China review after Phase III win | ||
| Mi | Redwire gains Aspera contract for space-based cancer research | ||
| Mi | Agenus and Zydus sign agreements for botensilimab and balstilimab | ||
| Mi | Magazine: Are regulators keeping pace with AI adoption in clinical trials? | ||
| Mi | Roche extends SMA market lead with Evrysdi tablet approval in Europe | ||
| Mi | EC approves Takeda ADC plus chemo for stage IIb Hodgkin's lymphoma | ||
| Di | ASCO25: AbbVie flexes ADC Phase I data as NSCLC market opportunity beckons | ||
| Di | SpyGlass Pharma secures $75m for ophthalmic drug delivery platform | ||
| Di | ASCO25: Kura's Phase II ziftomenib results trigger NDA acceptance from FDA | ||
| Di | ASCO25: Genmab's Rina-S en route to 'blockbuster potential' amid further positive data | ||
| Di | FDA grants expanded access to ImmunityBio's Anktiva for lymphopenia | ||
| Di | Regeneron to acquire rights for Hansoh's HS-20094 therapy | ||
| Mo | BMS outlays $11bn to join BioNTech's development of bispecific cancer drug | ||
| Mo | Sanofi to expand immunology offerings with Blueprint Medicines | ||
| Mo | ASCO25: J&J's Carvykti shows strong efficacy across multiple myeloma risk groups | ||
| Mo | Sanofi and Regeneron report results from two Phase III trials of COPD treatment | ||
| Mo | ASCO25: MSD's KRAS G12C drug shows early promise in Phase I | ||
| Mo | ASCO25: Regeneron unpacks positive Libtayo data in adjuvant CSCC as Keytruda stumbles | ||
| Mo | CirCode Biomed gains clearance from FDA for RNA drug HM2002 | ||
| Mo | Zymeworks' zanidatamab gains approval in China for biliary tract cancer | ||
| Fr | ASCO25: Pfizer's Braftovi combo boasts 47% drop in disease progression in mCRC | ||
| Fr | EyePoint advances with Duravyu Phase III trial | ||
| Fr | Alvotech and Advanz to commercialise biosimilars in Europe | ||
| Fr | FDA rejects Stealth Bio's Barth syndrome treatment after 16.5-month review | ||
| Fr | Astellas and Evopoint sign ADC licensing deal |
Sie erhalten auf FinanzNachrichten.de kostenlose Realtime-Aktienkurse von und .